Direct-to-Crystal: Accelerating Drug Discovery through Flexible Crystallography Approaches

Fast-Track Drug Discovery with Flexible, Integrated X-ray Crystallography

Discover how Sygnature Discovery accelerates structural biology workflows through flexible, project-specific X-ray crystallography. Learn how our Direct-to-Crystal (D2C) and HTS-to-Structure approaches support rapid hit validation, SAR development, and lead optimization.

Structure-guided drug design remains one of the most powerful approaches for advancing drug discovery, but the speed at which high-quality structural data can be generated is often a critical factor. At Sygnature Discovery, close integration between protein sciences, crystallography and wider drug discovery disciplines enables structural data to be generated and leveraged rapidly to inform key project decisions across target validation, hit identification and lead optimisation.

This work highlights a range of crystallographic approaches designed to increase efficiency and reduce turnaround times, resulting in:These strategies enable structural information to be obtained earlier in discovery programmes, helping teams prioritise compounds, understand binding modes and make more informed design decisions. Additional time savings are achieved through direct-to-crystal approaches that eliminate the need for compound purification prior to structural analysis, allowing binding data to be generated directly from crude reaction mixtures.

• Robust gene-to-structure pipelines
• Rapid hit validation workflows
• and direct-to-crystal methodologies

These strategies enable structural information to be obtained earlier in discovery programmes, helping teams prioritise compounds, understand binding modes and make more informed design decisions. Additional time savings are achieved through direct-to-crystal approaches that eliminate the need for compound purification prior to structural analysis, allowing binding data to be generated directly from crude reaction mixtures.

Explore real-world case studies showcasing how we have implemented these streamlined structural biology workflows to demonstrate how we can shorten design-make-test-analyse DMTA cycles and drive medicinal chemistry forward, fast.

Ongoing developments in automation and high-throughput crystallography are expected to further enhance the speed and impact of structure-guided drug discovery, enabling faster delivery of actionable structural insights to project teams.

Download the free poster to see how our structural biology platform empowers efficient, informed decision-making in early drug discovery.